文献速递湿疹皮炎与荨麻疹

巴瑞替尼联合外用糖皮质激素治疗儿童中重度特应性皮炎:III期随机双盲安慰剂对照研究(BREEZE-AD PEDS)

Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS).
PubMed 文献 · Br J Dermatol · 2023-01-01

该III期随机双盲安慰剂对照研究纳入483例2至<18岁中重度特应性皮炎患者,评估巴瑞替尼三种剂量联合低至中效外用糖皮质激素的疗效与安全性。巴瑞替尼4 mg等效剂量在全部16周终点上较安慰剂有统计学显著改善(P<0.05),因不良事件停药率低(安慰剂1.6%,巴瑞替尼0.6%),未观察到死亡、静脉血栓栓塞事件、动脉血栓事件、主要不良心血管事件、恶性肿瘤、胃肠道穿孔或机会性感染。

要点

  • 巴瑞替尼4 mg等效剂量联合外用糖皮质激素在16周时较安慰剂显著改善vIGA-AD 0/1、EASI-75、EASI-90、SCORAD 75等终点(P<0.05)。
  • 因不良事件停药率:安慰剂1.6%,巴瑞替尼0.6%;未观察到死亡、静脉血栓栓塞事件、动脉血栓事件、主要不良心血管事件、恶性肿瘤、胃肠道穿孔或机会性感染。
  • 巴瑞替尼可能为适合系统治疗的中重度特应性皮炎患儿提供一种具有有利获益-风险特征的治疗选择。

核心结论

  • 巴瑞替尼可能为适合系统治疗的中重度特应性皮炎患儿提供一种具有有利获益-风险特征的治疗选择。

研究设计与样本

  • III期随机双盲安慰剂对照研究,纳入483例2至<18岁中重度特应性皮炎患者,按1:1:1:1随机分配至巴瑞替尼低剂量(1 mg等效)、中剂量(2 mg等效)、高剂量(4 mg等效)或安慰剂每日一次治疗16周。

主要发现

  • 巴瑞替尼4 mg等效剂量在全部16周终点上较安慰剂有统计学显著改善(P<0.05),包括vIGA-AD 0/1且≥2分改善、EASI-75、EASI-90、SCORAD 75、EASI评分均值变化及≥10岁患者瘙痒NRS 4分改善。
  • 巴瑞替尼4 mg等效剂量较安慰剂在入睡能力和外用糖皮质激素使用减少方面也观察到改善(P<0.05,非多重性校正)。
  • 因不良事件停药的患者极少:安慰剂组1.6%,巴瑞替尼组0.6%。
  • 未观察到死亡、静脉血栓栓塞事件、动脉血栓事件、主要不良心血管事件、恶性肿瘤、胃肠道穿孔或机会性感染。

关键数值与推荐

  • 主要终点为第16周达到vIGA-AD 0/1且≥2分改善的患者比例。
  • 关键次要终点包括EASI-75、EASI-90、SCORAD 75、EASI评分均值变化及≥10岁患者瘙痒NRS 4分改善的比例。
  • 主要和关键次要疗效分析在意向治疗人群中进行并校正多重性;安全性分析纳入所有接受至少1剂研究药物的随机患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Baricitinib, an oral selective Janus kinase (JAK)1/JAK2 inhibitor, is approved in many countries for moderate-to-severe atopic dermatitis (AD) in adults who are candidates for systemic therapy. OBJECTIVES: To evaluate the efficacy and safety of three doses of baricitinib in combination with low-to-moderate potency topical corticosteroids in paediatric patients with moderate-to-severe AD. METHODS: Patients (aged 2 to < 18 years) were randomized (1 : 1 : 1 : 1) to once-daily baricitinib low dose (1 mg equivalent), medium dose (2 mg equivalent), high dose (4 mg equivalent) or placebo for 16 weeks. The primary endpoint was the proportion of patients achieving a validated Investigator Global Assessment® (vIGA-AD) of 0/1 with a ≥ 2-point improvement at week 16. Key secondary endpoints included the proportions of patients achieving ≥ 75% and ≥ 90% improvement in the Eczema Area and Severity Index (EASI-75 and EASI-90, respectively), ≥ 75% improvement in the SCORing Atopic Dermatitis (SCORAD 75), mean change from baseline in EASI score and proportion of patients achieving a 4-point improvement in the Itch Numeric Rating scale (NRS) for patients aged ≥ 10 years. Primary and key secondary efficacy analyses were conducted on the intent-to-treat population and adjusted for multiplicity. Safety analyses included all randomized patients who received ≥ 1 dose of study treatment. RESULTS: A total of 483 patients were randomized (mean age 12 years). The baricitinib 4 mg equivalent achieved a statistically significant (P < 0.05) improvement vs. placebo on all 16-week endpoints (vIGA 0/1 with ≥ 2-point improvement, EASI-75, EASI-90, SCORAD 75, mean change in EASI score and Itch NRS 4-point improvement for patients aged ≥ 10 years). Improvement (P < 0.05, non-multiplicity adjusted) was also observed for baricitinib 4 mg equivalent vs. placebo in the ability to fall asleep and in reduction of topical corticosteroid use. Few patients discontinued due to adverse events (1.6% for placebo and 0.6% for those treated with baricitinib). There were no deaths, venous thromboembolic events, arterial thrombotic events, major adverse cardiovascular events, malignancies, gastrointestinal perforations or opportunistic infections seen. CONCLUSIONS: The results indicate that baricitinib offers a potential therapeutic option with a favourable benefit-risk profile for paediatric patients with moderate-to-severe AD who are candidates for systemic therapies.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Torrelo A, Rewerska B, Galimberti M, et al. Efficacy and safety of baricitinib in combination with topical corticosteroids in paediatric patients with moderate-to-severe atopic dermatitis with an inadequate response to topical corticosteroids: results from a phase III, randomized, double-blind, placebo-controlled study (BREEZE-AD PEDS). Br J Dermatol. 2023. PMID: 36999560. doi:10.1093/bjd/ljad096

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。